MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:35Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Cephalosporins]]
			[[Category:Beta-lactam antibiotics]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #165

2026-05-23T03:56:07Z

parser-claude batch MedTemplate pre-fill, Top 300 #165

New page

{{MedTemplate
| generic = Cefdinir
| brand = Omnicef (discontinued in US under brand); mostly generic
| structure =
| classes = [[:Category:Cephalosporins|Cephalosporin (third-generation)]], [[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]]
| uses = <vote slug="otitis-media-use">Acute otitis media</vote>, <vote slug="strep-pharyngitis-use">Streptococcal pharyngitis</vote>, <vote slug="acute-sinusitis-use">Acute bacterial sinusitis</vote>, <vote slug="cap-use">Community-acquired pneumonia (mild outpatient)</vote>, <vote slug="ssti-use">Uncomplicated skin and soft-tissue infections</vote>
| starting_dose = 300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d
| preparations = 300 mg capsules; 125, 250 mg/5 mL suspension
| fda_max = 600 mg/d
| pill_id =
| routes = Oral
| onset = Hours
| duration = 12-24 hours
| halflife = ~1.7 hours<ref name="omnicef-label">FDA Prescribing Information, Omnicef (cefdinir), Abbott (originator), current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s019lbl.pdf</ref>
| bioavailability = 16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)<ref name="omnicef-label" />
| pregnancy = Generally considered safe in pregnancy.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="cefdinir-mech-claim">Cefdinir binds penicillin-binding proteins (PBPs) in the bacterial cell wall and inhibits transpeptidation of peptidoglycan cross-links; the result is bactericidal lysis of growing organisms.</vote> Third-generation cephalosporin spectrum: improved gram-negative coverage relative to first-generation cephalexin while preserving most gram-positive activity. Characteristic harmless red stool with concurrent iron ingestion (cefdinir-iron complex) is occasionally reported and not a sign of GI bleeding<ref name="omnicef-label" />.
}}

== References ==
<references />

Cefdinir - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #165